UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Judge Orders $5.8 Million Payment to E. Jean Carroll After Trump Loses Appeal Bid 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Dollar Rises as Middle East Conflict Fuels Inflation and Rate Hike Fears 
Trinidad Businessman Dominic Hadeed Appeals Detention Over Alleged Assassination Plot 
DOJ Seeks Dismissal of Gautam Adani Bribery Case, Citing Foreign Scope 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
China vs. NASA: The New Moon Race and What's at Stake by 2030 
Australian Business Conditions Hold Steady as Easing Cost Pressures Face New Oil Price Risks 
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1 
Tabletop particle accelerator could transform medicine and materials science 
Australia Consumer Sentiment Rises in July as Fuel Price Relief Lifts Confidence 
ICC Says Darfur War Crimes Probe Reaches Breakthrough in Sudan Investigation 
NASA's Artemis II Mission: First Crewed Lunar Journey Since Apollo 
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
